KZR
Kezar Life Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KZR
Kezar Life Sciences, Inc.
A clinical-stage biopharmaceutical company focus on treatments for immune-mediated and oncologic disorders
Pharmaceutical
02/19/2015
06/21/2018
NASDAQ Stock Exchange
55
12-31
Common stock
4000 Shoreline Court, Suite 300, South San Francisco, CA 94080
--
Kezar Life Sciences, Inc., was incorporated under the laws of the State of Delaware on February 19, 2015. The company is a clinical-stage biotechnology company developing novel small molecule therapies for the treatment of unmet needs in immune-mediated diseases and cancer. The company is advancing two drug development programs that utilize different regulators of cell function: the first targets the immunoproteasome, which is responsible for many key aspects of protein degradation in immune system cells and drives immune cell function, and the second targets the Sec61 transposon.
Company Financials
EPS
KZR has released its 2025 Q3 earnings. EPS was reported at -1.53, versus the expected -1.96, beating expectations. The chart below visualizes how KZR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
